Sorrento Therapeutics Inc

NASDAQ:SRNE  
1.59
+0.01 (+0.63%)
Products, Regulatory

Scilex Holding Co Announces Final Results For Sp-102 Semdexa Efficacy And Safety From Phase 3 Trial

Published: 03/18/2022 13:40 GMT
Sorrento Therapeutics Inc (SRNE) - Scilex Holding Company, a Majority-owned Subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for Sp-102 (semdexa™) Efficacy and Safety From Its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management Supporting the Potential for First to Market Opportunity.
Scilex Holding Company - Announced Significant Positive Final Results From Its Sp-102 Phase 3 Pivotal Trial Clear.
Program.
Scilex Holding Co - Sp-102 (semdexa™) Showed Continued Reduction of Pain Beyond One Month, and Median Time to Open-label Repeat Injection Was 99 Days.
Scilex Holding Co - Intends to Use Results From This Pivotal Phase 3 Trial to Discuss With FDA in 2022.